FDA approves Roche ’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer

Roche today announced that the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa ® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news